miRNAs: From Master Regulators of Gene Expression to Biomarkers Involved in Intercellular Communication

Levantini, Elena; Rizzo, Milena

doi:10.3390/biomedicines12040721

Biomedicines

2024

DOI: 10.3390/biomedicines12040721

|View full text |Cite

miRNAs: From Master Regulators of Gene Expression to Biomarkers Involved in Intercellular Communication

Elena Levantini,

Milena Rizzo

Abstract: MicroRNAs (miRNAs) are non-coding RNAs that act as master regulators of gene expression, fine-tuning the activity of thousands of genes in our cells, by modulating gene expression at the post-transcriptional level [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Towards personalized management of myasthenia gravis phenotypes: From the role of multi-omics to the emerging biomarkers and therapeutic targets

Balistreri,

Vinciguerra,

Magro

et al. 2024

Autoimmunity Reviews

View full text Add to dashboard Cite

Towards personalized management of myasthenia gravis phenotypes: From the role of multi-omics to the emerging biomarkers and therapeutic targets

Balistreri,

Vinciguerra,

Magro

et al. 2024

Autoimmunity Reviews

View full text Add to dashboard Cite

Regulation of HTT mRNA Biogenesis: The Norm and Pathology

Zubkova,

Yudkin

2024

IJMS

View full text Add to dashboard Cite

Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in exon 1 of the HTT gene, leading to the formation of a toxic variant of the huntingtin protein. It is a rare but severe hereditary disease for which no effective treatment method has been found yet. The primary therapeutic targets include the mutant protein and the mutant mRNA of HTT. Current clinical trial approaches in gene therapy involve the application of splice modulation, siRNA, or antisense oligonucleotides for RNA-targeted knockdown of HTT. However, these approaches do not take into account the diversity of HTT transcript isoforms in the normal conditions and in HD. In this review, we discuss the features of transcriptional regulation and processing that lead to the formation of various HTT mRNA variants, each of which may uniquely contribute to the progression of the disease. Furthermore, understanding the role of known transcription factors of HTT in pathology may aid in the development of potentially new therapeutic tools based on endogenous regulators.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

miRNAs: From Master Regulators of Gene Expression to Biomarkers Involved in Intercellular Communication

Abstract: MicroRNAs (miRNAs) are non-coding RNAs that act as master regulators of gene expression, fine-tuning the activity of thousands of genes in our cells, by modulating gene expression at the post-transcriptional level [...]

Cited by 2 publications

References 31 publications

Towards personalized management of myasthenia gravis phenotypes: From the role of multi-omics to the emerging biomarkers and therapeutic targets

Towards personalized management of myasthenia gravis phenotypes: From the role of multi-omics to the emerging biomarkers and therapeutic targets

Regulation of HTT mRNA Biogenesis: The Norm and Pathology

Contact Info

Product

Resources

About